
Reviewers

The Editor acknowledges the following reviewers for providing critical reviews of the various chapters of the book:

Zahid Ahmad Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA

Lars Berglund Department of Internal Medicine, University of California, Davis, Sacramento, CA, USA

Virgil Brown Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA

John D. Brunzell Department of Medicine, University of Washington, Seattle, WA, USA

Stephen R. Daniels Department of Pediatrics, University of Colorado, School of Medicine, Aurora, CO, USA

Fredrick Dunn Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA

Paul Durrington Department of Medicine, University of Manchester, Manchester, UK

Kenneth Feingold Department of Medicine, UCSF School of Medicine, University of California, San Francisco, CA, USA

Henry N. Ginsberg Department of Medicine, Columbia University, New York, NY, USA

John R. Guyton Department of Medicine, Duke University Medical Center, Durham, NC, USA

Helena Gylling Department of Medicine, University of Helsinki, Helsinki, Finland

Robert Hegele Department of Medicine, University of Western Ontario, London, Ontario, Canada

Peter H. Jones Department of Medicine, Baylor College of Medicine, Houston, TX, USA

Moti Kashyap Department of Medicine, University of California, Irvine, CA, USA

George A. Kaysen Departments of Internal Medicine, Biological Chemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, USA

Ronald Mensink Department of Human Biology, Maastricht University Medical Center, Maastricht, The Netherlands

Paul Nestel Baker IDI Heart and Diabetes Institute, Melbourne, Australia

Klaus G. Parhofer Department of Endocrinology and Metabolism, University of Munich, Munich, Germany

Anand Rohtagi Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA

Annabelle Rodriguez-Oquendo Department of Cell Biology, University of Connecticut, Farmington, CT, USA

Meena Shah Department of Kinesiology, Texas Christian University, Fort Worth, TX, USA

Patrizia Tarugi Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy

Gerald F. Watts Departments of Medicine and Pharmacology, University of Western Australia Perth, Australia

Shizuya Yamashita Departments of Community Medicine and Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

Index

A

- ABCG5 348, 467
- Abetalipoproteinemia 75, 77, 251, 252, 254, 255, 257, 261, 262
- Allele-specific apo(a) levels 31, 32, 34, 39
- Antilipolysis 440, 442, 444, 449
- Antiretroviral therapy (ART) 155, 158, 291
- Apo(a) genotype 32
- Apo(a) phenotype 31
- Apolipoprotein B (APOB) 1, 5, 8, 27, 29, 122, 253, 376
- Apolipoprotein E (APOE) 4, 6, 9, 79, 139, 186, 215, 223, 228
- Apolipoproteins 19, 60
- Atherosclerosis 8–11, 19, 31, 72, 85, 149, 195, 229, 241, 322, 444
- Atherosclerotic cardiovascular disease (ASCVD) 9, 28, 29, 31, 224, 226, 313, 351
- ATP-binding cassette protein A1 (ABCA1) 7, 9, 10, 346, 348, 443
- ATP-binding cassette transporter G5 (ABCG5) 10, 71, 236, 237, 239, 241, 345, 471
- Autosomal dominant hypercholesterolemia 88, 178

B

- Berardinelli-Seip Congenital Lipodystrophy 2 (BSCL2) 292, 296
- Bezafibrate 169, 217, 424, 425, 428, 433, 435
- Bile Acid Sequestrants (BAS) 90, 129, 194, 207, 322, 350, 453, 454
- Bile acids 10, 31, 69, 90, 144, 196, 237, 247, 277, 315, 347, 394, 453, 455

C

- Campesterol 71, 235, 343, 345, 471
- Cardiovascular disease (CVD) 4, 6, 13, 19, 31, 39, 40, 42, 57
- Cardiovascular risk 6, 13, 18, 26, 30, 41, 44, 61, 163, 221, 276, 330, 407
- Cataracts 80, 243, 247
- Chenodeoxycholic acid (CDCA) 245, 246, 248, 455
- Cholesterol absorption 68, 69, 108, 170, 344, 345, 347, 348, 350, 465–470, 473
- Cholesterol Ester Transfer Protein (CETP) 8–10, 59, 80, 81, 105, 226, 227, 229, 317, 512

- Chronic kidney disease (CKD) 17, 39, 142, 229, 431, 445, 474
- Chylomicron retention disease (CRD) 77, 251–253, 257, 262
- Circulating lipoproteins 58
- Colesevelam 90, 316, 351, 454, 460, 475
- Colestipol 69, 90, 448, 454, 455, 475
- Coronary artery disease (CAD) 30, 58, 61, 68, 100, 192
- Coronary heart disease (CHD) 4, 9, 13, 30, 57, 146, 228, 253, 415

D

- Diabetic dyslipidemia 104, 107
- Diacylglycerol acyltransferase 1 (DGAT1) 2, 3, 472, 507, 508
- Dietary Supplement 87, 330, 383, 396, 507
- Disorders involving abnormal ldl receptor activity 90, 184, 195, 272, 350
- Disorders of low hdl and high triglycerides 226
- Docosahexaenoic acid (DHA) 91, 299, 337, 338
- Drug-induced dyslipidemia 277
- Dyslipidemia 57, 61, 67, 72, 74, 83, 85–87, 91, 100, 118, 126
- Dyslipoproteinemia 67, 80, 82, 84, 92

E

- Effect of dietary and drug treatment 71
- Eicosapentaenoic acid (EPA) 91, 218, 299, 337
- Endothelial function 87, 148, 351, 371, 377, 378
- Estrogen 270
- Etc-1002 500, 508
- Ezetimibe 68, 71, 89, 90, 147, 241, 315, 322, 345, 350, 446, 453, 465, 466, 468–475

F

- Familial defective apoB-100 (FDB) 178, 184
- Familial hypercholesterolemia 16, 19, 43, 58, 194, 236, 313, 483
- Familial hypobetalipoproteinemia 58, 76, 77, 251–253, 256, 257, 262
- Farnesoid X receptor (FXR) 394, 454
- Fatty acids 1–5, 43, 75, 108, 209, 262, 388, 507

Fenofibrate 107, 149, 217, 276, 318, 424, 425, 428–430, 432, 433, 475
 Fibrates 78, 80, 107, 148, 169, 217, 318, 424, 431, 500
 Fish oil 75, 91, 170, 217, 275, 299, 337, 500
 Flavonoids 372, 374, 377, 379

G

G protein-coupled receptor (GPR109A) 440, 441, 443
 Gemfibrozil 91, 129, 148, 149, 169, 217, 299, 412, 424, 425, 428, 430, 432, 434, 456
 Genetic susceptibility 213–216, 227
 Genetic variants 17, 19, 34, 39, 40, 58, 215
 Genetics 21, 117, 221, 312
 Genome-wide association studies (GWAS) 40, 304
 Glucocorticoids 269, 270, 272
 Guidelines 61, 109, 193, 329

H

HDL function 142, 221, 229
 Hemodialysis 137, 140–144, 146, 147, 500
 Hepatic lipase (HL) 6, 8, 78, 119, 138, 141, 157, 158, 223, 228
 Hepatic steatosis 77, 226, 257, 262, 270, 292, 296, 504
 High density lipoproteins (HDL) 6, 13, 58, 221, 267
 Human Immunodeficiency Virus (HIV) 155, 156, 159–161, 165, 294
 Hyperalphalipoproteinemia 228
 Hypercholesterolemia 13, 81, 188, 192, 196, 271, 315, 394, 470
 Hypertriglyceridemia 78
 Hypertriglyceridemia (HTG) 16, 57, 68, 72, 73, 77, 78, 80, 124, 128, 141, 144, 157, 165, 205, 228, 273, 276, 296, 508
 Hypobetalipoproteinemia 16, 76, 77, 252, 253, 255, 259, 261, 503

I

Inflammation 156, 157, 164, 223, 270, 351, 371, 406, 442
 Inhibitor 149, 169, 170, 277, 502, 504, 508, 512
 Insulin deficiency 115, 119, 124
 Insulin resistance 18, 57, 85, 91, 100, 104, 115, 119, 127, 128, 170, 261, 320, 503
 Intestinal cholesterol transporter 466

L

LDL apheresis 69, 71, 483–487, 489, 490, 493
 LDL cholesterol 5, 6, 31, 41, 43, 44, 107, 156, 169, 178, 188, 192, 194, 195, 218, 344, 348–350, 489
 LDL receptor 2, 4, 6, 43, 71, 139, 179, 181, 195, 223, 467
 LDL receptor adaptor protein 1 (LDLRAP1) 71, 181, 195
 Lecithin cholesterol acyltransferase (LCAT) 8, 80, 81, 223, 225, 486
 Lipid and lipoprotein metabolism 138, 140, 374, 375

Lipid lowering drugs 188, 315, 499
 Lipid-lowering 105, 109, 471
 Lipid-lowering therapy 90, 275, 315, 418, 507
 Lipid-lowering treatment 44, 106, 109, 110, 194, 269
 Lipids 13, 348, 500, 502
 Lipodystrophy 159, 161–163, 270, 287, 292–294, 296, 299
 Lipoprotein lipase (LPL) 3, 5, 17, 69, 119, 140, 158, 424
 Lipoproteins 1, 502, 509
 LMNA 292, 293, 296
 Lomitapide 70, 194, 504, 507
 Low cholesterol 13, 79, 348
 Low density lipoprotein (LDL) 25, 251, 493, 509, 510
 Low-density lipoprotein cholesterol (LDL-C) 119, 186, 303, 403
 Low-density lipoproteins (LDLs) 1, 67, 188

M

Macrothrombocytopenia 241
 Metabolism 1, 3, 5, 7, 138–140, 142, 144, 185, 222, 374, 458, 468, 470
 Microsomal triglyceride transfer protein (MTP) 3, 5, 70, 75, 317, 318, 507
 Mipomersen 43, 69, 194, 317, 502
 Molecular mechanisms 5, 137, 296, 469
 Mutation 4, 70, 80, 184, 186, 192, 216, 251, 262, 292, 311

N

Nephrotic syndrome 81, 91, 121, 137–139, 143, 499
 Niacin 41, 59, 91, 108, 149, 218, 229, 413, 439, 442, 444, 445, 448
 Nicotinic acid 41, 43, 91, 108, 170, 218, 445
 Niemann-Pick C1 Like 1 (NPC1L1) 2, 10, 90, 241, 345, 347, 465, 467, 469
 Non-alcoholic fatty liver disease (NAFLD) 466
 Non-alcoholic steatohepatitis (NASH) 466, 474

O

Obesity 13, 16, 57, 73, 83, 85, 87, 104, 115, 116, 125, 178, 212, 217, 227
 Oligogenic dyslipidemia 83
 Omega-3 fatty acids 80, 91, 108, 169, 218, 322

P

Peritoneal dialysis 140, 142–144, 148
 Phytosterols 235, 343–345, 347, 348, 350
 Plant stanols 343–345, 349, 350, 407
 Plant sterols 10, 68, 87, 236, 240, 241, 343, 467, 471
 Postprandial hyperlipidemia 466, 472, 478
 Primary prevention 318, 319, 338
 Progression of kidney disease 137
 Proprotein convertase subtilisin/kexin type 9 (PCSK9) 58, 70, 71, 76, 177, 185, 273, 511
 Protease inhibitors (PI) 89, 158, 165, 277, 409
 Proteinuria 81, 121, 137, 142, 146, 149

R

Regulation 5, 7, 31, 120, 237
Remnants 2, 4, 5, 72, 73, 79, 105, 140, 141, 196, 223, 346, 467
Renal transplantation 137, 270
Retinoids 212, 274
Risk assessment 57, 60, 61, 319–321, 330
Risk factors 13, 18, 30, 41, 57, 61, 67, 83, 87, 100, 127, 166, 187, 217, 499

S

Secondary prevention 105, 108–110, 145, 313–315, 318, 336, 385, 407, 417, 474
Single nucleotide polymorphism (SNP) 19, 34, 61, 304
Sirolimus 144, 272, 273
Sitostanol 343–345
Sitosterol 71, 235, 240, 241, 343–345, 465, 471
Smith-Lemli-Opitz syndrome 242
Soy isoflavones 374, 377, 380, 390
Statin intolerance 70, 393, 461, 511
Statins 41–43, 68, 72, 89, 106, 107, 144–146, 148, 405, 407, 471
Stilbene trans-resveratrol 371, 377, 380

T

Tea catechins 374, 377, 380
Triglycerides 17, 60, 103
Triglycerides-rich lipoproteins 1, 2, 100, 144, 269, 299
Type 1 diabetes (T1D) 115, 117, 118, 350
Type 2 diabetes (T2D) 57, 73, 87, 100, 103, 105, 108, 458, 474

V

Very low density lipoproteins (VLDL) 1, 100, 119, 140, 251, 314

X

Xanthomas 68, 69, 71, 79, 80, 187, 188, 214, 236, 245, 248, 287

Z

Zinc metalloproteinase (ZMPSTE24) 161, 294